BioWorld MedTech

2 days ago | bioworld.com | Brian Orelli

Home » Abvance Therapeutics secures seed funding to limit glucose lows BioWorld briefs for June 26, 2025. BioWorld MedTech briefs for June 25, 2025. Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric... BioWorld Asia briefs for June 24, 2025 Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another.

3 days ago | bioworld.com | Marian Chu

Home » Abion strikes $1.3B antibody drug deal with unidentified partner BioWorld briefs for June 25, 2025. BioWorld MedTech briefs for June 24, 2025. Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...

4 days ago | bioworld.com | Annette Boyle

ADA 2025Two new options presented at ADA for early diagnosis of T1DClassically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose levels.

4 days ago | bioworld.com | Annette Boyle

ADA 2025AID system improves glycemic control in pregnancyPregnant women with type 1 diabetes who used a hybrid closed loop automated insulin delivery system averaged more than three additional hours per day in their recommended glucose range than those who managed their diabetes with insulin injections or non-automated pump systems, a study presented at the 85th Scientific Sessions of the American Association in Chicago demonstrated.

4 days ago | bioworld.com | Marian Chu

Home » Moderna expands mRNA tech to latent viruses, cancer, rare disease BioWorld briefs for June 23, 2025. BioWorld MedTech briefs for June 23, 2025. BioWorld Asia briefs for June 24, 2025 Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd.... In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc.